Herpes simplex virus 1 strain 17+ with R2 mutation in UL37 has residual retrograde transport
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.01959-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Marius Walter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Herpes Simplex, Viral Structural Proteins. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Herpes simplex virus 1 (HSV-1) causes lifelong recurrent infections. Following primary infection of the oral or genital mucosa, HSV-1 travels retrogradely through axons and establishes latency in the cell body of ganglionic neurons of the peripheral nervous system. Periodic reactivation in neurons and anterograde transport of virions back to peripheral regions cause oral or genital ulcerations. Many host and viral factors implicated in retrograde and anterograde transport of HSV-1 have been identified. In particular, studies reported that introducing five amino acid substitutions in the R2 region of the viral tegument protein UL37 was sufficient to completely eliminate retrograde transport of HSV-1 strain F. Here, we introduced the same R2 mutations in the highly neurovirulent HSV-1 strain 17+. We show that this R2 17 virus is highly attenuated in mice and acts as a potent vaccine that protects mice against acute HSV-1 infection. However, we report that the R2 17 virus has residual retrograde transport. We show that R2 17 can establish latency in mouse models of ocular and vaginal infection and reactivate. These results contradict published evidence and show that the R2 mutation is not sufficient to fully prevent retrograde transport of HSV-1. IMPORTANCE Herpes simplex virus 1 (HSV-1) is a ubiquitous pathogen without a cure or vaccine. HSV-1 travels through nerves between the oral and genital mucosa and the peripheral nervous system, where it establishes lifelong latency. Studies reported that introducing five amino acid substitutions in the R2 region of the viral tegument protein UL37 was sufficient to completely eliminate the retrograde transport of HSV-1 strain F from the mucosa to the nervous system. Here, we present contradictory findings. We report that an HSV-1 virus from strain 17+ with the same R2 mutation has residual retrograde transport. This shows that the R2 mutation is not sufficient to fully prevent the retrograde transport of HSV-1 in all settings. This finding may be particularly relevant for assessing the safety of prospective live-attenuated vaccines that include the R2 mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Marius Walter
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Walter, M., Haick, A. K., Massa, P. A., Klouser, L. M., Stensland, L., Santo, T. K., Xie, H., & Jerome, K. R. (2026). Herpes simplex virus 1 strain 17+ with R2 mutation in UL37 has residual retrograde transport. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01959-25
Vancouver
Walter M, Haick AK, Massa PA, Klouser LM, Stensland L, Santo TK, et al. Herpes simplex virus 1 strain 17+ with R2 mutation in UL37 has residual retrograde transport. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01959-25
BibTeX
@article{Walter2026,
author = {Walter, Marius and Haick, Anoria K and Massa, Paola A and Klouser, Lindsay M and Stensland, Laurence and Santo, Tracy K and Xie, Hong and Jerome, Keith R},
title = {Herpes simplex virus 1 strain 17+ with R2 mutation in UL37 has residual retrograde transport},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.01959-25}
}
EUVIMED